Tiziana 生命科学的鼻部抗体可能有助于减少阻止GLP-1糖尿病药品的副作用。 Tiziana Life Sciences' nasal antibody may help reduce side effects from stopping GLP-1 diabetes drugs.

Tiziana Tiziana生命科学发现,其鼻部抗CD3单克隆抗体在阻止用于治疗代谢紊乱的GLP-1激动剂时可能有助于减少副作用。 Tiziana Life Sciences has found that its nasal anti-CD3 monoclonal antibody may help reduce side effects when stopping GLP-1 agonists, which are used to treat metabolic disorders. 治疗方法是鼻内注射福拉马, 显示其有潜力维持组织健康, 减少肌肉损失和骨密度下降等问题. The treatment, intranasal foralumab, shows potential in maintaining tissue health and reducing issues like muscle loss and bone density decrease. 这将使GLP-1型药物的使用对病人更加容易接受和有效。 This could make GLP-1 drug use more tolerable and effective for patients.